Clinical trials: Semaglutide
Overweight, Obesity
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease.
- Trial name
- SELECT (NCT03574597)
- Testing
- Semaglutide
- Where
- 833 sites in United States, Algeria and 40 more
- Volunteers
- 17,604 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months).
- Trial name
- NCT06269120
- Testing
- Oral Semaglutide
- Where
- 19 sites in Hungary
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested.
- Trial name
- NCT07817251
- Testing
- CagriSema
- Where
- 40 sites in United States
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.
- Trial name
- NCT02064348
- Testing
- semaglutide, moxifloxacin
- Where
- Germany
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity.
- Trial name
- WeGoReal (NCT07081178)
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo).
- Trial name
- NCT04969939
- Testing
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- Where
- 25 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine.
- Trial name
- NCT03842202
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Nausea and Vomiting, Obesity
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one…
- Trial name
- NCT07446439
- Testing
- Tradipitant
- Where
- 10 sites in United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Adults With Overweight/Obesity and Type 2 Diabetes
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes.
- Trial name
- NCT07724340
- Testing
- AT673 low dose, AT673 high dose
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Antag Therapeutics
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
- Trial name
- NCT06716216
- Testing
- Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC
- Where
- China
- Volunteers
- 537 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
The trial is conducted in Europe. The aim of the trial is to investigate the influence of semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of single doses of atorvastatin and digoxin in healthy…
- Trial name
- NCT02243098
- Testing
- semaglutide, digoxin, atorvastatin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE SPAIN (NCT04067999)
- Testing
- Semaglutide
- Where
- 16 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema.
- Trial name
- REIMAGINE 5 (NCT06534411)
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 163 sites in United States, Argentina and 12 more
- Volunteers
- 1,023 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02161588
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S